clinical trial · NCT07659379
Gotistobart Long Term Extension (LTE) Study
OncoC4, Inc.·phase3·enrolling by invitation·n = 20
Advanced Solid TumorGotistobart
brief summary
This LTE study will examine the long-term overall survival and safety of gotistobart in patients with advanced solid tumors.
started
Jul 28, 2026
primary completion
Jul 1, 2036
completion
Jan 1, 2037
last updated
Aug 24, 2026
detailed description
This is a multi-center, open-label, long term extension study of gotistobart (ONC-392 / BNT316) in participants with advanced or metastatic tumors. The purpose of this trial is to roll over patients who previously enrolled in OncoC4-sponsored gotistobart trials, including those who received gotistobart or gotistobart-based combinations, into an extension trial to collect long-term overall survival and safety data.
official title
Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in Gotistobart Trials
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol